Jensen, L. H., Olesen, R., Petersen, L. N., Boysen, A. K., Andersen, R. F., Lindebjerg, J., . . . Hansen, T. F. (2019). NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. Cancers (Basel).
Citação norma ChicagoJensen, Lars Henrik, et al. "NPY Gene Methylation As a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit From Last-Line Treatment With Regorafenib in Metastatic Colorectal Cancer." Cancers (Basel) 2019.
Citação norma MLAJensen, Lars Henrik, et al. "NPY Gene Methylation As a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit From Last-Line Treatment With Regorafenib in Metastatic Colorectal Cancer." Cancers (Basel) 2019.